

## **IRB Relying Site Continuing Review Worksheet**

**Purpose of this form:** This form is to be completed by the relying study site team at the time of Continuing Review. The completed form is to be submitted to the MetroHealth Lead Study Team for inclusion in the overall Continuing Review application.

**Instructions:** Section A is to be completed by MetroHealth Lead Study Team. Sections B through H are to be complete by the relying site study staff in coordination with the relying site IRB. Sections not applicable to the study or to the relying site's role in the study should be marked "N/A."

A. Protocol Information (To be com	pleted by MHS study staff)
Protocol Title:	
MHS IRB Number:	
Funding Source:	
MHS Principal Investigator:	
MHS PI Phone:	
MHS PI Email:	
MHS Study Staff Contact:	
MHS Contact Phone:	
MHS Contact Email:	
MHS IRB Email:	IRBReliance@metrohealth.org



B. Relying Site Institution Information performance site)	ion (Sections B through H are to be completed by relying	
Name of Institution:		
Address of Institution:		
FWA Number:		
IRB Contact:		
IRB Contact Email:		
IRB Contact Phone:		
C. Relying Site Contact Information		
Relying Site Principal Investigator:		
Site PI Phone:		
Site PI email:		
Site Study Staff Point of Contact:		
Site Study Staff Phone:		
Site Study Staff Email:		



Principal Investigator		Human Subjects Research Training (Expiration Date)		Financial Conflict? (If yes, provide details in section)	
, ,			Yes	No	
			Yes	No	
			Yes	No	
			Yes	No	
			Yes	No	
			Yes	No	
			Yes	No	
			Yes	No	
riate credentials and/or q s standards for eligibility t	ualifications,	Yes	N	lo	
eccano sereny					
	riate credentials and/or q	Institution who are involved in this riate credentials and/or qualifications, is standards for eligibility to conduct details below)	riate credentials and/or qualifications, s standards for eligibility to conduct  Yes	Yes  Yes  Yes  Yes  Yes  Yes  Yes  Yes	



Ε.	Sul	bject Accrual
	1.	How many subjects have been enrolled at your site since study initiation?
	2.	How many subjects remain active in the study at your site?
	3.	How many subjects had been enrolled at your site since the last Continuing Review?
	4.	How many subjects have completed the study at your site?
	5.	How many subjects have withdrawn from the study at your site since the last Continuing Review? Withdrawal refers both to subjects who decide to withdraw from participation and subjects who are withdrawn by the investigator. If subjects have withdrawn, provide the reason for each withdrawal in the text box below.
	6.	Summarize any difficulties in recruitment/retainment and any study related complaints:



F.	Reportable Events
	1. Have there been any reportable events at your site since the last Continuing Review that HAVE NOT been reported to the MetroHealth Lead Study Team? Reportable Events include Adverse Events, Protocol Deviations, Unanticipated Problems, and Breaches of Confidentiality. If yes, what is the current overall status of review and approval by the applicable ancillary committee(s)?
	If yes, provide details below for each Reportable Event in the text box below. Additional information may be required:



G.	Data Security		
1.	Have you made any changes to your data security plan (how and where data is stored)? If yes, describe in the text box below.	Yes	No

Н.	Additional Comment
1.	Provide any additional information relevant to the study that you may wish to include in the text box below.